PlainPharmaWatch

CMS Open Payments · Program Year 2024

Boehringer Ingelheim Espana S.A.

Boehringer Ingelheim Espana S.A. reported $382,770.85 across General Payments, Research, and Ownership to 2 physicians and teaching hospitals across 32 transactions.

See the rankings → How this is sourced
$382.8K
All-tracks total
32
Transactions
2
Recipients
#837
of 1,925 companies

Boehringer Ingelheim Espana S.A. reported $382,770.85 across all CMS Open Payments tracks (General + Research + Ownership) to 2 physicians and teaching hospitals in Program Year 2024 - ranking #837 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,575.36, averaging $191.4K per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer boehringer-ingelheim-espana-s-a Boehringer Ingelheim Espana S.A.

$382.8K · #837/1,925 · 0.0% industry · PY2024

  • TOT $382.8K
  • RANK #837
  • SHARE 0.0%
  • TXN 32
  • RCP 2
  • CAT 1
  • GEN $1.6K
  • TOP1 61.5%
  • PY 2024

Volume peers

Nearest volume peer: Vifor Pharma, Inc. ($383.6K)

Vifor Pharma, Inc.$383.6KBoehringer Ingelheim Espana …$382.8KFlower Orthopedics Coporation$381.4KCraniUS LLC$379.4KElekta Instrument AB$379.2K
All-tracks payment totals near Boehringer Ingelheim Espana S.A. (CMS Open Payments PY2024)

Boehringer Ingelheim Espana S.A. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for Boehringer Ingelheim Espana S.A.

In Program Year 2024, Boehringer Ingelheim Espana S.A. reported $382,770.85 in payments to 2 physicians and teaching hospitals across 32 individual transactions, an average of $12.0K per transaction and $191.4K per recipient. That total places Boehringer Ingelheim Espana S.A. at rank #837 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

The 1-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Compensation for Services Other Than Consulting" at $1.6K, accounting for 100.0% of this company's General Payments and 2 transactions.

General Payment Breakdown by Type

"Compensation for Services Other Than Consulting" leads Boehringer Ingelheim Espana S.A.'s 1-category general-payment breakdown at $1.6K, 100.0% of the reported total.

How Boehringer Ingelheim Espana S.A. divides its payments

How the reported total splits across payment categories

1. Compensation for Services…$1.6K
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $1.6K 2

Recipient Concentration in General Payments

The five largest recipient relationships account for $1,575.36 (100.0%) of $1,575.36 in this company's General Payments records across 2 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Boehringer Ingelheim Espana S.A.

The five named recipients with the highest reported General Payments from this company

Stephen Marder$969.45Christoph U Correll$605.91
  1. 1

    Stephen Marder

    $969.45 across 1 reported transactions

  2. 2

    Christoph U Correll

    $605.91 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Boehringer Ingelheim Espana S.A.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Boehringer Ingelheim Espana S.A..

Gyrus ACMI, Inc.

HHI 5269

Partner Therapeutics, Inc.

HHI 5272

BioPoly LLC

HHI 5258

AppliedVR Inc

HHI 5275

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Boehringer Ingelheim Espana S.A..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Boehringer Ingelheim Espana S.A.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.